[artículo] 
inJournal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 229-232

Título :	Ziprasidone metabolism, aldehyde oxidase, and clinical implications
Tipo de documento:	texto impreso
Autores:	Christine Beedham, Autor ; Jeffrey J. Miceli, Autor ; R. Scott Obach, Autor
Fecha de publicación:	2023
Artículo en la página:	pp. 229-232
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Etiquetas:	Sistema enzimático citocromo P-450, Interacciones farmacológicas, Piperazinas, Tiazoles.
Resumen:	Ziprasidone (Geodon, Zeldox), a recently approved atypical antipsychotic agent for the treatment of schizophrenia, undergoes extensive metabolism in humans with very little (<5%) of the dose excreted as unchanged drug. Two enzyme systems have been implicated in ziprasidone metabolism: the cytosolic enzyme, aldehyde oxidase, catalyzes the predominant reductive pathway, and cytochrome P4503A4 (CYP3A4) is responsible for two alternative oxidation pathways.
Link:	./index.php?lvl=notice_display&id=31018

[artículo] Ziprasidone metabolism, aldehyde oxidase, and clinical implications [texto impreso] / Christine Beedham, Autor ; Jeffrey J. Miceli, Autor ; R. Scott Obach, Autor . - 2023 . - pp. 229-232.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 229-232

Etiquetas:	Sistema enzimático citocromo P-450, Interacciones farmacológicas, Piperazinas, Tiazoles.
Resumen:	Ziprasidone (Geodon, Zeldox), a recently approved atypical antipsychotic agent for the treatment of schizophrenia, undergoes extensive metabolism in humans with very little (<5%) of the dose excreted as unchanged drug. Two enzyme systems have been implicated in ziprasidone metabolism: the cytosolic enzyme, aldehyde oxidase, catalyzes the predominant reductive pathway, and cytochrome P4503A4 (CYP3A4) is responsible for two alternative oxidation pathways.
Link:	./index.php?lvl=notice_display&id=31018